A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
NCT02055066 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2017-04-21
Summary
This a first-in-human study of an antibody blocking the function of the oncogene c-met in patients with cancer.
Conditions
Interventions
- DRUG
-
ARGX-111
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ahmad Awada, MD · Jules Bordet Institute
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2017-03-31
- Completion
- 2017-03-31
Countries
- Belgium
Study Locations
More Related Trials
-
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
NCT03689192 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
NCT05483530 ·Status: UNKNOWN ·Phase: PHASE1
-
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones
NCT00720031 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
NCT05360680 ·Status: COMPLETED ·Phase: PHASE1
-
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05102214 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
NCT05614258 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
NCT01847118 ·Status: UNKNOWN ·Phase: PHASE1
-
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
NCT00967577 ·Status: COMPLETED ·Phase: PHASE1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
NCT00095108 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
NCT00051675 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
NCT00145145 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
NCT00492440 ·Status: TERMINATED ·Phase: PHASE1
-
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00311545 ·Status: WITHDRAWN ·Phase: PHASE2
-
Multiepitope Peptide Vaccination in Melanoma
NCT00153569 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
NCT03588650 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
NCT02580747 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
NCT06126666 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients
NCT00306566 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT03126110 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
NCT01288989 ·Status: COMPLETED ·Phase: PHASE1
-
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
NCT01191034 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
NCT00782002 ·Status: COMPLETED ·Phase: PHASE1